Literature DB >> 22156733

Weighed, measured, and still searching: bevacizumab in the treatment of unselected patients with advanced breast cancer.

Gilberto Lopes1, Rebecca Dent.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22156733      PMCID： PMC3248764          DOI： 10.1634/theoncologist.2011-0403

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  9 in total

Review 1.  Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.

Authors:  Vishal Ranpura; Sanjaykumar Hapani; Shenhong Wu
Journal:  JAMA       Date:  2011-02-02       Impact factor: 56.272

Review 2.  Bevacizumab in the treatment of metastatic breast cancer: friend or foe?

Authors:  Alberto J Montero; Mauricio Escobar; Gilberto Lopes; Stefan Glück; Charles Vogel
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

3.  Progression-free survival remains debatable endpoint in cancer trials.

Authors:  Rabiya Tuma
Journal:  J Natl Cancer Inst       Date:  2009-10-14       Impact factor: 13.506

4.  Bevacizumab for advanced breast cancer: all tied up with a RIBBON?

Authors:  Harold J Burstein
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

5.  The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy.

Authors:  Shaheenah Dawood; Asim Jamal Shaikh; Thomas A Buchholz; Javier Cortes; Massimo Cristofanilli; Sudeep Gupta; Ana M Gonzalez-Angulo
Journal:  Cancer       Date:  2011-10-05       Impact factor: 6.860

6.  Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.

Authors:  Nicole Mittmann; Heather-Jane Au; Dongsheng Tu; Christopher J O'Callaghan; Pierre K Isogai; Christos S Karapetis; John R Zalcberg; William K Evans; Malcolm J Moore; Jehan Siddiqui; Brian Findlay; Bruce Colwell; John Simes; Peter Gibbs; Matthew Links; Niall C Tebbutt; Derek J Jonker
Journal:  J Natl Cancer Inst       Date:  2009-08-07       Impact factor: 13.506

Review 7.  Bevacizumab treatment for advanced breast cancer.

Authors:  Ricardo H Alvarez; Valentina Guarneri; Fikri Icli; Stephen Johnston; David Khayat; Sibylle Loibl; Miguel Martin; Christoph Zielinski; PierFranco Conte; Gabriel N Hortobagyi
Journal:  Oncologist       Date:  2011-10-05

Review 8.  Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.

Authors:  J Cortes; V Calvo; N Ramírez-Merino; J O'Shaughnessy; A Brufsky; N Robert; M Vidal; E Muñoz; J Perez; S Dawood; C Saura; S Di Cosimo; A González-Martín; M Bellet; O E Silva; D Miles; A Llombart; J Baselga
Journal:  Ann Oncol       Date:  2011-10-04       Impact factor: 32.976

9.  Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation.

Authors:  Konstantin J Dedes; Klazien Matter-Walstra; Matthias Schwenkglenks; Bernhard C Pestalozzi; Daniel Fink; Peter Brauchli; Thomas D Szucs
Journal:  Eur J Cancer       Date:  2009-01-13       Impact factor: 9.162
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.